Literature DB >> 14592821

Vav1: an oncogene that regulates specific transcriptional activation of T cells.

Shulamit Katzav1.   

Abstract

The nuclear factor of activated T cells (NFAT) proteins are a family of transcription factors whose activation is controlled by calcineurin, a Ca2+-dependent phosphatase. Once dephosphorylated, these proteins move to the nucleus where they interact with cofactors to form transcription factor complexes. Inhibition of NFAT proteins by immunosuppressants, such as cyclosporin A (CsA) and FK506, is used clinically to prevent transplant rejection. Although these drugs have revolutionized organ transplantation, their use is associated with severe side effects in other organs in which NFAT proteins are important. One of the signal transducers that controls NFAT activity is Vav1, which is exclusively expressed in the hematopoietic system. Vav1 contains numerous modular domains that enable its function as a guanine exchange factor (GEF) toward RhoGTPases as well as participate in protein-protein interactions. This review focuses on the mechanisms by which Vav1 regulates NFAT through GEF-dependent and -independent cascades, emphasizing the newly assigned role of Vav1 in the regulation of Ca2+ release. Because of its restriction to hematopoietic cell lineages and its importance in the regulation of NFAT, targeting Vav1 and, in particular, its association with other proteins may offer a highly selective means of modifying T-cell behavior, thus allowing the development of more specific immunosuppressive therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592821     DOI: 10.1182/blood-2003-08-2834

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Two closely spaced tyrosines regulate NFAT signaling in B cells via Syk association with Vav.

Authors:  Chih-Hong Chen; Victoria A Martin; Nina M Gorenstein; Robert L Geahlen; Carol Beth Post
Journal:  Mol Cell Biol       Date:  2011-05-23       Impact factor: 4.272

Review 2.  Calcium-dependent activation of T-lymphocytes.

Authors:  Ariel Quintana; Désirée Griesemer; Eva C Schwarz; Markus Hoth
Journal:  Pflugers Arch       Date:  2004-11-26       Impact factor: 3.657

3.  Vav Guanine nucleotide exchange factors regulate atherosclerotic lesion development in mice.

Authors:  Shaik O Rahaman; Wei Li; Roy L Silverstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-03       Impact factor: 8.311

4.  The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells.

Authors:  Jie Yin; Ya-juan Wan; Shi-yang Li; Ming-juan Du; Cui-zhu Zhang; Xing-long Zhou; You-jia Cao
Journal:  Acta Pharmacol Sin       Date:  2010-12-13       Impact factor: 6.150

5.  Evidence of off-target effects of bosutinib that promote retinoic acid-induced differentiation of non-APL AML cells.

Authors:  Noor Kazim; Andrew Yen
Journal:  Cell Cycle       Date:  2021-11-26       Impact factor: 4.534

6.  Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.

Authors:  Sonia Guedan; Aviv Madar; Victoria Casado-Medrano; Carolyn Shaw; Anna Wing; Fang Liu; Regina M Young; Carl H June; Avery D Posey
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

7.  Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion.

Authors:  Shulamit Sebban; Marganit Farago; Shiran Rabinovich; Galit Lazer; Yulia Idelchuck; Lena Ilan; Eli Pikarsky; Shulamit Katzav
Journal:  Oncotarget       Date:  2014-10-15

Review 8.  Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.

Authors:  Shulamit Katzav
Journal:  Oncotarget       Date:  2015-10-06

9.  Hierarchical nanostructure and synergy of multimolecular signalling complexes.

Authors:  Eilon Sherman; Valarie A Barr; Robert K Merrill; Carole K Regan; Connie L Sommers; Lawrence E Samelson
Journal:  Nat Commun       Date:  2016-07-11       Impact factor: 14.919

10.  Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes.

Authors:  Batel Shalom; Marganit Farago; Eli Pikarsky; Shulamit Katzav
Journal:  Oncogenesis       Date:  2018-10-08       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.